By structural magnetic resonance imaging (MRI), we aim to understand Multiple Sclerosis (MS) at the systemic level. We quantify tissue damage to better monitor the heterogeneous course of MS and to relate these measurements to biomarkers with the ultimate goal to bridge the gap between molecular and systemic neuroscience in the field of MS research.
Schmidt, P, Gaser, C, Arsic, M, Buck, D, Förschler, A, Berthele, A, Hoshi, M, Ilg, R, Schmid, VJ, Zimmer, C, Hemmer, B, Mühlau, M (2012). An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis. Neuroimage 59: 3774-83.
Hemmer, B, Mühlau, M (2017). Multiple sclerosis in 2016: Immune-directed therapies in MS - efficacy and limitations. Nat Rev Neurol 13: 72-4.
Righart, R, Pongratz nee Biberacher, V, Jonkman, LE, Klaver, R, Schmidt, P, Buck, D, Berthele, A, Kirschke, JS, Zimmer, C, Hemmer, B, Geurts, JJG, Mühlau, M (2017). Cortical pathology in multiple sclerosis detected by the T1/T2-weighted ratio from routine magnetic resonance imaging. Annals of neurology 82: 519-29.
Grahl, S, Bussas, M, Wiestler, B, Eichinger, P, Gaser, C, Kirschke, J, Zimmer, C, Berthele, A, Hemmer, B, Mühlau, M. (2021). Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics 18: 2589-2597.
Bussas, M, Grahl, S, Pongratz, V, Berthele, A, Gasperi, C, Andlauer, T, Gaser, C, Kirschke, JS, Wiestler, B, Zimmer, C, Hemmer, B, Mühlau, M (2022). Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers. Mult Scler, 28: 900-909.